← All trials
NCT03664518
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2018
- Primary completion
- Oct 31, 2019
- Completion date
- May 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 58
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- Henan Medical UniversityCollaborator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- Shandong UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- Nanjing UniversityCollaborator
- University of Science and Technology of ChinaCollaborator
- Kunming Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- China Academy of Chinese Medical SciencesOfficial
- NovartisCollaborator
- China Academy of Chinese Medical SciencesSponsor investigator
- North China University of Science and Technology Affiliated HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.